Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Knightscope
Sponsored
content by Knightscope
MA
MarketJar
Community Contributor
The Next Phase of Defense AI: A Robotic Response to America’s Security Gaps
Autonomous systems are no longer just a futuristic vision — they’re fast becoming an essential layer of national security. As AI reshapes everything from finance to warfare, physical security remains one of the most under-addressed frontiers.
View narrative
US$12.00
FV
54.3% undervalued
intrinsic discount
22.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
1
users have commented on this narrative
15
users have followed this narrative
New
narrative
Figma
TI
TickerTickle
Community Contributor
Figma (FIG): The S&P 500’s Design Standard Turning Into an All-in-One Platform
Watching Figma Grow Up I’ve been using Figma almost every single day for the past five years. As a product designer, it’s been my main tool for designing interfaces, testing and prototyping ideas, and also for working together with teams in different countries and time zones.
View narrative
US$65.70
FV
7.2% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
Updated
narrative
Sleep Cycle
MA
Mandelman
Community Contributor
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Update Q1 2025 (updated 250510) The latest user‐growth data suggest headwinds for top-line revenue, but management’s active repricing initiatives should help offset this. By combining modest user gains with targeted price increases, the company can still drive overall revenue growth.
View narrative
SEK 38.04
FV
25.3% undervalued
intrinsic discount
3.15%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
23
users have followed this narrative
Updated
narrative
JB Hi-Fi
RO
Robbo
Community Contributor
Has JB Hi-Fi Lost Its Point of Difference?
I may be showing my age here, but I feel that a decade or so ago, shopping at JB Hi-Fi was a different experience. There seemed to be a deliberate policy of employing sales staff from alternative subcultures, which gave the stores a unique, edgy vibe.
View narrative
AU$76.00
FV
51.4% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
SSR Mining
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Uncertain Çöpler Restart And Rising Costs Will Strain Outlook
Key Takeaways Prolonged operational uncertainty, rising costs, and regulatory pressures threaten earnings, limit cash flow recovery, and erode long-term profitability. Shifting global energy trends and environmental scrutiny increase risks around demand, delays, and margin compression for SSR Mining's core business.
View narrative
CA$14.72
FV
64.9% overvalued
intrinsic discount
13.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Sandoz Group
AN
AnalystLowTarget
Consensus Narrative from 14 Analysts
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
Key Takeaways Sustained pricing and regulatory pressures, along with rising legal risks, are likely to constrain revenue growth and earnings quality for Sandoz. Increased investment and competition may erode margins and threaten the long-term viability of its traditional generics and biosimilars business model.
View narrative
CHF 37.09
FV
36.3% overvalued
intrinsic discount
4.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Zevra Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Sluggish Diagnosis Will Constrain Expansion But Bring Cautious Optimism
Key Takeaways Reliance on rare disease therapies limits growth due to narrow patient pools, slow diagnoses, and physician awareness, posing risks to stable revenue and earnings expansion. High operating and R&D expenses, coupled with competitive pressures and payer resistance, threaten profit margins and may weaken future financial flexibility.
View narrative
US$18.00
FV
48.0% undervalued
intrinsic discount
60.09%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
VIK
Viking Holdings
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Aggressive Fleet Expansion Will Erode Margins Amid Overcapacity
Key Takeaways Stricter environmental rules, shifting travel trends, and demographic risks threaten profitability and demand stability for Viking Holdings. Aggressive fleet expansion amid rising competition may cause overcapacity, margin pressure, and unpredictable returns.
View narrative
US$53.00
FV
13.3% overvalued
intrinsic discount
13.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Monde Nissin
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Regulatory And Cost Headwinds Will Hinder Long-Term Stability
Key Takeaways Growing health concerns and regulatory pressures threaten traditional product lines, while shifting consumer preferences favor premium and fresh alternatives. Rising costs, fierce competition, and sustainability demands risk compressing margins and market share, especially amid weak pricing power and innovation gaps.
View narrative
₱6.50
FV
12.0% overvalued
intrinsic discount
2.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Tidewater Renewables
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Electrification And Overcapacity Will Erode Margins Even As British Columbia Rules Cushion Declines
Key Takeaways Accelerating electrification and emerging battery technologies threaten core demand, while global competition and regulatory changes heighten operational and revenue risks. Industry overcapacity and concentrated contract reliance may trigger margin erosion, underutilization, and instability in servicing growing debt.
View narrative
CA$3.50
FV
1.7% overvalued
intrinsic discount
22.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
KCB Group
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Rising Geopolitical And Fintech Risks Will Undermine Future Prospects
Key Takeaways Geopolitical instability, currency volatility, and rising compliance demands threaten KCB's asset quality, revenue growth, and cost efficiency across its regional operations. Intensifying fintech competition and slow digital innovation risk eroding KCB's market share, fee income, and long-term earnings potential.
View narrative
KSh44.00
FV
22.7% overvalued
intrinsic discount
12.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Assertio Holdings
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Rising Pricing Pressures And Portfolio Exposure Will Test Future Recoveries
Key Takeaways Heavy dependence on a concentrated drug portfolio and mounting pricing pressures create major risks to future revenue stability and profitability. Regulatory scrutiny, generic competition, and shifting payer policies threaten Assertio's ability to offset margin pressure despite operational improvements and acquisition potential.
View narrative
US$1.50
FV
47.6% undervalued
intrinsic discount
5.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
BRC
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Tariff Pressures And Costs Will Challenge Operations And Spark Change
Key Takeaways Shifting consumer habits toward at-home coffee and health concerns over energy drinks could limit demand in key BRC product segments and pressure growth. Reliance on major direct-to-consumer and wholesale accounts, as well as inflation and supply chain pressures, may heighten revenue volatility and constrain margin improvement.
View narrative
US$1.75
FV
9.1% undervalued
intrinsic discount
14.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies